Enrofloxacin, which was first synthesized by Bayer researchers Grohe and Peterson in 1980, has been developed exclusively for use in veterinary medicine. Introduced to the market in 1988, it has become the most important quinolone for the therapy of bacterial infections in animals worldwide.
Baytril® interferes with bacterial DNA metabolism by inhibition two enzymes: topoisomerase II (also called DNA gyrase) and topoisomerase IV.
Enrofloxacin is a synthetic 6-fluoroquinolone. The core structure is identical to nalidixic acid. As a result of gradual changes in the basic structure, antimicrobial potency and pharmacokinetics have substantially been improved, whereas unwanted effects were reduced.